tradingkey.logo
tradingkey.logo
Search

Trinity Biotech PLC

TRIB
Add to Watchlist
0.574USD
-0.009-1.59%
Close 05/15, 16:00ETQuotes delayed by 15 min
11.63MMarket Cap
LossP/E TTM

Trinity Biotech PLC

0.574
-0.009-1.59%
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-1.59%

5 Days

-5.36%

1 Month

-17.84%

6 Months

-34.65%

Year to Date

-27.38%

1 Year

-32.20%

TradingKey Stock Score of Trinity Biotech PLC

Currency: USD Updated: 2026-05-15

Key Insights

Trinity Biotech PLC's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 158 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Trinity Biotech PLC's Score

Industry at a Glance

Industry Ranking
158 / 206
Overall Ranking
464 / 4482
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Trinity Biotech PLC Highlights

StrengthsRisks
Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
Growing
The company is in a growing phase, with the latest annual income totaling USD 43.78M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 43.78M.
Overvalued
The company’s latest PE is -0.11, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 876.37K shares, decreasing 70.31% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 20.26K shares of this stock.

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Trinity Biotech PLC News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Trinity Biotech PLC Info

Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
Ticker SymbolTRIB
CompanyTrinity Biotech PLC
CEOGillard (John)
Websitehttps://www.trinitybiotech.com/
KeyAI